Vimarsana
Biggest News Aggregation in the World

Page 14 - Practice Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Practice Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Practice Research Today - Breaking & Trending Today

​​​​​​​MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of T - Vimarsana News

​​​​​​​MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of T

DGAP-News: MorphoSys AG / Key word(s): Miscellaneous/Conference11.12.2021 / 18:00 The issuer is solely responsible for the content of this announcement.MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatme...

MorphoSys AG: MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Vimarsana News

MorphoSys AG: MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

- RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies- Results from the retrospective cohort analysis indicate significant

Incyte und MorphoSys melden Eingang der von der Europäischen Kommission erteilten Zulassung für Minjuvi (Tafasitamab) in Kombination mit Lenalidomid zur Behandlung von Erwachsenen mit rezidiviertem oder refraktärem diffusem großzelligem... - Vimarsana News

Incyte und MorphoSys melden Eingang der von der Europäischen Kommission erteilten Zulassung für Minjuvi (Tafasitamab) in Kombination mit Lenalidomid zur Behandlung von Erwachsenen mit rezidiviertem oder refraktärem diffusem großzelligem...

- Entscheidung der Kommission basiert auf Daten aus der Studie L-MIND zur Prüfung von Minjuvi in Kombination mit Lenalidomid als Behandlung von Patienten mit rezidiviertem oder refraktärem DLBCL -

Role for GPs in heart-risk hunt - Vimarsana News

Role for GPs in heart-risk hunt

Date Time Role for GPs in heart-risk hunt GP clinics could be enlisted to help identify patients unknowingly at risk of a premature heart attack and early death due to an inherited condition, a Department of Health-funded study has found. The newly published research found that GP clinics could not only play a pivotal role in identifying patients with the condition familial hypercholesterolaemia (FH), but also in managing their ongoing treatment. Lead researcher and Notre Dame Professor of General Practice Research, Tom Brett said FH was a lifelong condition in which the liver’s ability to ...

Sağlıklı Kilo Vermenin 10 Yolu! - Vimarsana News

Sağlıklı Kilo Vermenin 10 Yolu!

Sağlıklı Kilo Vermenin 10 Yolu! Eklenme Tarihi: 12.07.2021 01:39 Güncellenme: 12.07.2021 01:41 Sağlıklı Kilo Vermenin 10 Yolu! Özellikle teknoloji söz konusu olduğunda, birçok kaynağın mevcut olduğu bir dünyada yaşıyoruz. Ne yazık ki, tüm bu gelişmeler hareket ihtiyacını azaltarak hareketsiz kalmamıza neden oldu.   1. Düşük Karbonhidrat Alımı En iyi diyet planını belirlerken proteinler, karbonhidratlar ve yağlar anlamına gelen ana besin gruplarını dikkate almalısınız. Hızlı kilo verme...